Management of the adverse effects of antiretroviral therapy and medication adherence

Clinical Infectious Diseases

Volumn 30, Issue , 2000, Pages S96-S116

  Max, Blake ^a,b   Sherer, Renslow ^a  

^a RUSH MEDICAL COLLEGE   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ADEFOVIR DIPIVOXIL; AMPRENAVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIRETROVIRUS AGENT; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; HYDROXYUREA; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ANEMIA; CONFERENCE PAPER; DRUG MONITORING; DRUG SAFETY; FEVER; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY FAILURE; METABOLIC DISORDER; PATIENT COMPLIANCE; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RASH; THROMBOCYTOPENIA;

ANTI-HIV AGENTS; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; PATIENT COMPLIANCE; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 0034456735     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/313859     Document Type: Article

References (171)

1. Marked declines in human immunodeficiency virus-related mortality in Chicago in Women, African Americans, Hispanics, Young Adults, and Injection Drug Users from 1995 through 1997
2. Monitoring the epidemic of HIV/AIDS in the US: Current status and future prospects
3. Report of the NIH panel to define principles of therapy of HIV infection and guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents
4. New antiretroviral therapies: Adherence, challenges and strategies
5. Incidence and predictors of virologic failure to indinavir or ritonavir in an urban health clinic
6. Adherence issues in HIV therapeutics
7. Survey of side effects and their impact on medication adherence
8. Survey of patients and physicians attitudes and experience with adherence
9. Perceived health care providers support and HIV adherence
10. How much adherence is enough? A prospective study of adherence to protease inhibitor therapy using memscaps
11. Assessing and enhancing compliance with antiretroviral therapy
12. Adherence, antiretroviral therapy, and injection drug use
13. Adherence: The Achilles heel of highly active antiretroviral therapy
14. The Midwest AIDS training and education partners adherence initiative
15. Interventions and patient outcomes from a pharmacist-based HIV medication and adherence referral clinic
16. Comparison of mitochondrial morphology, mitochondrial DNA content, and cell viability in cultured cells treated with three anti-human immunodeficiency virus dideoxynucleosides
17. Adverse effects of reverse transcriptase inhibitors: Mitochondrial toxicity as common pathway
18. Human DNA polymerases alpha and beta are able to incorporate anti-HIV deoxynucleotides into DNA
19. Ziagen/combivir is equivalent to indinavir/combivir in antiretroviral therapy (ART) naive adults at 24 weeks (CNA3005)
20. Hepatomegaly and steatosis in HIV-infected patients receiving nucleoside analog antiretroviral therapy
21. Zidovudine-induced fatal lactic acidosis and hepatic failure in patients with acquired immunodeficiency syndrome: Report of two patients and review of the literature
22. Lactic acidosis associated with stavudine administration: A report of five cases
23. Mitochondrial toxicity of antiviral drugs
24. Pharmacokinetics of zidovudine in patients with liver cirrhosis
25. Dosage adjustment of antiretroviral agents in patients with organ dysfunction
26. The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection: A double-blind, placebo-controlled trial
27. The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial
28. Zidovudine: Five years later
29. Zidovudine in asymptomatic human immunodeficiency virus infection: A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter
30. Pathogenesis and pathophysiology of anemia in HIV infection
31. Changing etiology of macrocytosis: Zidovudine as a frequent causative factor
32. Prognosis in AZT myopathy
33. Cardiomyopathy associated with antiretroviral therapy in patients with HIV infection: A report of six cases
34. Nail pigmentation changes associated with azidothymidine (zidovudine)
35. Recombinant human erythropoietin in the treatment of anemia associated with human immunodeficiency virus (HIV) infection and zidovudine therapy
36. Combined therapy with recombinant granulocyte colony-stimulating factor and erythropoietin decreases hematologic toxicity from zidovudine
37. Randomized trial of addition of lamivudine or lamivudine plus loviride to zidovudine containing regimens for patients with HIV-1 infection: The CAESAR trial
38. DDI once daily vs twice daily alone and also with hydroxyurea once daily
39. Stavudine and didanosine combination therapy in HIV-infected subjects: Antiviral efficacy and safety in an ongoing pilot randomized double-blinded trial
40. Fatal case of 2,3-dideoxyinosine-associated pancreatitis
41. Pancreatic disease in AIDS: A review
42. Five-year follow-up of a phase 1 study of didanosine in patients with advanced human immunodeficiency virus infection
43. Hyperosmolar nonketotic diabetic syndrome following treatment of human immunodeficiency virus infection with didanosine
44. Stavudine-didanosine-nevirapine: A convenient highly active triple combination for first line antiretroviral therapy
45. Safety and tolerance of dideoxycytidine as an agent: Results of early-phase studies in patients with acquired immunodeficiency syndrome (AIDS) or advanced AIDS-related complex
46. Peripheral neuropathy with nucleoside antiretrovirals
47. Zalcitabine compared with zidovudine in patients with advanced HIV-1 infection who received previous zidovudine therapy
48. A comparative trial of didanosine or zalcitabine after treatment with zidovudine in patients with human immunodeficiency virus infection
49. Dermatologic complications associated with administration 2′,3′-dideoxycytidine in patients with human immunodeficiency virus infection
50. Biologic effects and safety of stavudine: Overview of phase I and II clinical trials
51. Stavudine in patients with AIDS and AIDS-related complex: AIDS Clinical Trials Group 089
52. 2,3-Didehydro-3-deoxythymidine (d4T) in patients with AIDS or AIDS-related complex: A phase 1 trial
53. Clinical efficacy of monotherapy with stavudine compared with zidovudine in HIV-infected, zidovudine-experienced patients: A randomized, double-blind, controlled trial
54. Nucleoside analogue-associated peripheral neuropathy in human immunodeficiency virus
55. Risk factors for dideoxynucleoside-induced toxic neuropathy in patients with the human immunodeficiency virus infection
56. The didanosine expanded access program: Safety analysis
57. Stavudine induced macrocytosis
58. Nucleoside analogue-associated peripheral neuropathy in human immunodeficiency virus infection
59. Efficacy of desipramine in painful diabetic neuropathy: A placebo-controlled trial
60. Depression in patients with HIV infection
61. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus
62. Trial of recombinant human nerve growth factor for HIV-associated sensory neuropathy
63. Mexiletine for HIV-infected patients with painful peripheral neuropathy: A double-blind, placebo-controlled, crossover treatment trial
64. Effects of (-)-2′-deoxy-3′-thiacytidine (3TC) 5′-triphosphate on human immunodeficiency virus reverse transcriptase and mammalian DNA polymerases alpha, beta, and gamma
65. A randomized, double-blind, placebo-controlled trial of lamivudine in combination with zidovudine, stavudine, or didanosine in treatment-naive patients
66. Evaluation of safety and efficacy of 3TC (lamivudine) in patients with asymptomatic or mildly symptomatic human immunodeficiency virus infection: A phase 1/2 study
67. A phase II, double-blind, placebo-controlled, dose ranging study to assess antiviral efficacy and safety of DMP-266 in combination with open-label zidovudine and lamivudine
68. A one-year trial of lamivudine for chronic hepatitis B
69. +cells per cubic millimeter
70. Combination therapy with abacavir (1592), 141W94, and AZT/3TC in subjects acutely and chronically infected with HIV-1
71. Preliminary long-term open-label data patients using abacavir (1592, ABC)-containing antiretroviral treatment regimens
72. Anaphylaxis after re-challenge with abacavir
73. A phase III, multicenter, randomized, open-label study to compare the antiretroviral activity and tolerability of efavirenz (EFV) + indinavir (IDV), versus EFV + zidovudine (ZDV) + lamivudine (3TC), versus IDV + ZDV + 3TC at 48 weeks (study DMP 266-006)
74. Location of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase
75. Current clinical experience with nevirapine for HIV infection
76. The VIRGO trial: D4T/ddi (qd)/nevirapine (bid or qd) in antiretroviral naive HIV-1-infected patients: A convenient and potent regimen
77. Nevirapine induced methadone withdrawal: Implications for antiretroviral treatment of opiate dependent HIV infected patients
78. A controlled trial of nevirapine plus zidovudine versus zidovudine alone in p24 antigenaemic HIV-infected patients
79. A randomized, double-blind trial of combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients (the INCAS trial)
80. Nevirapine: A review of its development, pharmaceutical profile and potential for clinical use
81. Nevirapine-induced overlap Stevens-Johnson syndrome/toxic epidermal necrolysis
82. Nevirapine-induced hepatitis treated with corticosteroids
83. ACTG 260: A randomized, phase I-II dose-ranging trial of the anti-human immunodeficiency virus activity of elavirdine monotherapy
84. Randomized, controlled phase I/II trial of combination therapy with delavirdine (U-90152S) and conventional nucleosides in human immunodeficiency virus type 1-infected patients
85. Microsomal metabolism of delavirdine: Evidence for mechanism-based inactivation of human cytochrome P450 3A
86. Summary of pharmacokinetic drug interaction studies with efavirenz
87. The potential impact of efavirenz on methadone maintenance
88. HIV-protease inhibitors
89. Toward HIV eradication or remission: The tasks ahead
90. Presentation to the panel to develop guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents
91. The rate of decline of HIV1 RNA in plasma correlates with nelfinavir concentrations in plasma
92. Plasma concentrations of saquinavir determine failure of response to saquinavir combination therapy
93. Virologic response-plasma drug concentration in phase III study of nelfinavir mesylate
94. First comparative study of saquinavir soft-gel capsules versus indinavir as part of triple therapy regimen (CHEESE)
95. Treatment with indinavir, zidovudine, and lamivudine: Three year follow-up
96. Indinavir can be taken with regular meals when administered with ritonavir
97. Frequency of lipodystrophy and factors associated with glucose/lipid abnormalities in a cohort of 650 patients treated with protease inhibitors
98. The efficacy of VIRACEPT (nelfinavir mesylate) in pivotal phase II/III, double-blind, randomized controlled trials as monotherapy and in combination with D4T or AZT/3TC
99. Long-term comparison of BID and TID dosing of VIRACEPT (nelfinavir) in combination with stavudine and lamivudine in HIV patients
100. Indinavir 12 hour dosing an alternative to 8 hourly dosing regimen: A pilot study
101. Ritonavir plus saquinavir in protease-inhibitor-naive patients after 72 weeks
102. Combination therapy containing ritonavir plus saquinavir has superior short-term antiretroviral efficacy: A randomized trial
103. Two year follow up of RIT + SAQ + 2 NRT1s therapy: Viral load, CD4 outcomes, metabolic complications, and implications for salvage
104. Quadruple therapy with saquinavir soft gel capsules plus nelfinavir versus triple therapy with either SQV-SGC or NFV alone in patients with ARV experience or high baseline viral load
105. Combining ritonavir and indinavir decreases IDV associated nephrolithiasis
106. Efficacy and safety of first line indinavir and ritonavir plus double nucleoside combination therapy in HIV infected individuals
107. Multiple dose pharmacokinetics and tolerability of indinavir ritonavir combinations in healthy volunteers
108. Co-administration of indinavir 1200 mg and nelfinavir 1250 mg in a twice daily regimen: Preliminary safety, pharmacokinetic, and antiviral activity
109. Prevalence and severity of protease inhibitor induced lipodystrophy and insulin resistance
110. New-onset diabetes mellitus associated with the use of protease inhibitor
111. Severe hyperglycemia in an HIV clinic: Preexisting versus drug-associated diabetes mellitus
112. Benign symmetric lipomatosis associated with protease inhibitors
113. Indinavir-associated lipodystrophy
114. Marked hypertriglyceridemia associated with ritonavir therapy
115. "Buffalo hump" in men with HIV-1 infection
116. Changes in body habitus in HIVinfected patients treated with protease inhibitors
117. HIV protease inhibitor-related lipodystrophy syndrome
118. Lipodystrophy associated with HAART: Correlation with duration of NRTI therapy
119. Severe premature coronary artery disease with protease inhibitors
120. Lipid abnormalities associated with use of protease inhibitors: Prevalence, clinical sequelae, and treatment
121. Distribution in lipid metabolism due to HIV infection and its therapy
122. Experience with National Cholesterol Education Program guidelines for the identification and treatment of protease inhibitor related lipid abnormalities: Results of a prospective study
123. Improvement of lipodystrophy in HIV-1-infected subjects switching from 2 NRTI/P1 to 2 NRTI/abacavir
124. Impact of switching from HIV-1 protease inhibitors (P1) to efavirenz ((EFV) in patients with lipodystrophy)
125. Management of protease inhibitor-associated metabolic changes by substitutions with efavirenz in virologically controlled HIV-1 RNA-positive patients
126. A pilot study of hydroxyurea among patients with advanced human immunodeficiency virus (HIV) disease receiving chronic didanosine therapy: Canadian HIV trials network protocol 080
127. Hydroxyurea in combination regimens for the treatment of antiretroviral-naive, HIV-infected individuals
128. Hydroxyurea (Hydrea)
129. The safety and efficacy of adefovir dipivoxil, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adults: Randomized, double-blind, placebo-controlled trial
130. Inhibitory effects of 9-(2phosphonylmethoxyethyl)-adenine (PMEA) on human and duck hepatitis B virus infection
131. Safety of adefovir dipivoxil in the treatment of HIV infection
132. The Preveon expanded access program: Safety of adefovir dipivoxil in ARV experienced patients with advanced HIV disease
133. Gilead 408: Adefovir dipivoxil added to standard therapy
134. Placebo-controlled multicenter trial of adefovir dipivoxil in patients with HIV disease
135. Pharmacokinetic evaluation of SQV-SGC/RIT of SQV/NLF in combination with DLV and/or adefovir dipivoxil - ACTG 359
136. Treat HIV-1 like other infections: Treat it
137. The case for conservative management of early HIV disease
138. HIV/AIDS in 1998 - Gaining the upper hand?
139. Antiretroviral drug resistance testing in adults with HIV infection: Implications for clinical management
140. Correlations of virological response with genotype and phenotype of plasma HIV-1 variants in patients treated with nelfinavir in the US expanded access program
141. Virologic and clinical implications of resistance to HIV-1 protease inhibitors
142. HIV treatment failure: Testing for HIV resistance in clinical practice
143. Antiretroviral drug resistance testing in adults with HIV infection: Implications for clinical management
144. Drug-resistance genotyping in HIV-1 therapy: The VIRADAPT randomized controlled trial
145. A pilot study of the short-term effects of antiretroviral management based on plasma genotypic antiretroviral resistance testing (GART) in patients failing antiretroviral therapy
146. Phenotypic resistance testing significantly improves response to therapy: A randomized trial (VIRA3001)
147. Use of phenotypic resistance assays after virologic failure of highly active antiretroviral therapy is associated with improved virologic response: The VIRADAPT study